6-甲基氨基嘌呤阿拉伯糖苷 | 60209-41-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: 6-甲基氨基嘌呤阿拉伯糖苷
• 英文名称: 9-<β-D-Arabinofuranosyl>-6-methylamino-9H-purin
• 英文别名: 1-(6-methylamino-purin-9-yl)-β-D-1-deoxy-arabinofuranose；9-(β-D-arabinofuranosyl)-6-methylamino-9H-purine；(2R,3S,4S,5R)-2-(hydroxymethyl)-5-[6-(methylamino)purin-9-yl]oxolane-3,4-diol
• CAS: 60209-41-8
• 化学式: C₁₁H₁₅N₅O₄
• 分子量: 281.271
• InChiKey: VQAYFKKCNSOZKM-ICQCTTRCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  126
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Therapeutic azide compounds
  申请人：University of Georgia Research Foundation, Inc.

  公开号：US20010036930A1

  公开（公告）日：2001-11-01

  Pharmaceutical prodrug compositions are provided comprising azide derivatives of drugs which are capable of being converted to the drug in vivo. Azide derivatives of drugs having amine, ketone and hydroxy substituents are converted in vivo to the corresponding drugs, increasing the half-life of the drugs. In addition azide prodrugs are often better able to penetrate the blood-brain barrier than the corresponding drugs. Especially useful are azide derivatives of cordycepin, 2′-F-ara-ddI, AraA, acyclovir, penciclovir and related drugs. Useful azide prodrugs are azide derivatives of therapeutic alicyclic amines, ketones, and hydroxy-substituted compounds, including aralkyl, heterocyclic aralkyl, and cyclic aliphatic compounds, where the amine or oxygen moiety is on the ring, or where the amine or oxygen moiety is on an aliphatic side chain, as well as therapeutic purines and pyrimidines, nucleoside analogs and phosphorylated nucleoside analogs.

  提供了药物前药组成物，其中包括具有可在体内转化为药物的药物的偶氮衍生物。具有胺基，酮基和羟基取代基的药物的偶氮衍生物在体内转化为相应的药物，增加了药物的半衰期。此外，偶氮前药通常比相应的药物更能穿过血脑屏障。特别有用的是cordycepin，2'-F-ara-ddI，AraA，acyclovir，penciclovir和相关药物的偶氮衍生物。有用的偶氮前药是治疗性脂环烷胺，酮和羟基取代化合物的偶氮衍生物，包括芳基烷基，杂环芳基烷基和环状脂肪族化合物，其中胺基或氧原子基团位于环上，或胺基或氧原子基团位于脂肪侧链上，以及治疗性嘌呤和嘧啶，核苷类似物和磷酸化核苷类似物。
• Antiviral compounds
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0294114A2

  公开（公告）日：1988-12-07

  The present invention relates to certain substituted purine arabinosides and their pharmaceutically acceptable derivatives especially esters and their use in the treatment and prophylaxis of varicella zoster virus and cytomegalovirus infections. The invention also includes pharmaceutical formulations and processes for the preparation of such compounds.

  本发明涉及某些取代的嘌呤阿拉伯苷及其药学上可接受的衍生物，特别是酯类，以及它们在治疗和预防水痘带状疱疹病毒和巨细胞病毒感染中的用途。本发明还包括制备此类化合物的药物制剂和工艺。
• Novel arabinosyladenine derivatives
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP0967220A1

  公开（公告）日：1999-12-29

  [Objects] An object of the present invention is to offer an Ara-A derivative having a resistance to the metabolism by ADA and also having a sufficient antiviral action. [Constitution] A novel 2-substituted arabinosyladenine derivative represented by the formula (I) and pharmaceutically acceptable salts and hydrates thereof. [In the formula, Z is alkyl having more than 4 carbon atoms, alkenyl or alkynyl and R is hydrogen or lower alkyl.] [Merit] The compounds of the present invention are Ara-A derivatives having a resistance to the metabolism by ADA and having a sufficient antiviral action whereby the problems in the prior art have been solved. The compounds of the present invention are useful as therapeutic or preventive agents for diseases infected by DNA virus such as herpes simplex virus (HSV), herpes zoster virus, cytomegalovirus (CMV), adenovirus, hepatitis virus or vaccinia virus. As compared with Ara-A, they not only show a good behavior in blood with an excellent sustaining property but also are capable of being orally administered whereby their usefulness is very high.

  目的 本发明的目的是提供一种 Ara-A 衍生物，该衍生物具有抗 ADA 代谢的能力，并具有足够的抗病毒作用。 构成 一种由式(I)代表的新型 2-取代的阿拉伯核糖基腺嘌呤衍生物及其药学上可接受的盐和水合物。 [式中，Z 为具有 4 个以上碳原子的烷基、烯基或炔基，R 为氢或低级烷基。］ 优点 本发明的化合物是 Ara-A 衍生物，具有抗 ADA 代谢的能力和足够的抗病毒作用，从而解决了现有技术中存在的问题。本发明的化合物可作为治疗或预防 DNA 病毒感染疾病的药物，如单纯疱疹病毒（HSV）、带状疱疹病毒、巨细胞病毒（CMV）、腺病毒、肝炎病毒或疫苗病毒。与 Ara-A 相比，它们不仅在血液中表现良好，具有出色的持续性，而且能够口服给药，因此具有很高的实用性。
• THERAPEUTIC AZIDE COMPOUNDS
  申请人：UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

  公开号：EP0852499A1

  公开（公告）日：1998-07-15
• US5424295A
  申请人：——

  公开号：US5424295A

  公开（公告）日：1995-06-13